<DOC>
	<DOC>NCT01789918</DOC>
	<brief_summary>The ACHIEVE study is a single-arm, open-label, prospective, post-market follow-up study to include up to one hundred (100) eligible patients as defined within the clinical investigational plan, with a twelve month follow-up period. The ACHIEVE study was originally designed in accordance with the 2007 ESH ESC guidelines for resistant hypertension.</brief_summary>
	<brief_title>TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Resistant hypertension, as defined in the 2007 ESHESC guidelines 18 years of age or older Negative pregnancy test for female patients of childbearing potential Willing and able to comply with followup requirements Signed informed consent Secondary hypertension Main renal arteries length &lt; 20 mm Main renal arteries diameter &lt; 4 mm Renal artery stenosis Iliac/femoral artery stenosis precluding insertion of the catheter Untreated allergy to contrast media Currently participating in the study of an investigational drug or device Moderate to severe renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Blood pressure</keyword>
	<keyword>Renal denervation</keyword>
</DOC>